<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725631</url>
  </required_header>
  <id_info>
    <org_study_id>2016GR0302</org_study_id>
    <nct_id>NCT03725631</nct_id>
  </id_info>
  <brief_title>Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD</brief_title>
  <official_title>Non-invasive Evaluation of Liver Fibrosis, Steatosis, and Nonalcoholic Steatohepatitis in Biopsy-Proven NAFLD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate hepatic fibrosis and steatosis using MR imaging, transient elastography
           (TE), and serum biomarker

        2. To develop non-invasive diagnosis marker for NASH and advanced fibrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of chronic liver
      disease, non-invasive diagnosis of disease severity in NAFLD is urgently needed. In this
      study, the investigators compared hepatic fibrosis and steatosis using MR imaging and
      transient elastography (TE) and tried to find non-invasive diagnostic marker for NASH and
      advanced fibrosis.

      This is a multicenter prospective study of patients with biopsy-proven NAFLD. The patients
      were underwent laboratory test, liver biopsy, MRI and TE within 6 months of enrollment. MRI
      examination included MR spectroscopy (MRS), and MR elastography (MRE). TE measured liver
      stiffness and controlled attenuation parameter (CAP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of scoring system for diagnosis of NASH</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Development of scoring system for diagnosis of NASH using cox regression analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hepatic fibrosis using fibroscan</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessment of hepatic fibrosis using fibroscan with transient elastography (kilopascals) (kPa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hepatic steatosis using fibroscan</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessment of hepatic steatosis using fibroscan with CAP (Controlled Attenuation Parameter) (dB/m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hepatic fibrosis using MRI</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessment of hepatic fibrosis using MRI with MR elastography (MRE) (kPa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hepatic steatosis using MRS</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessment of hepatic steatosis using fibroscan with MR spectrography (MRS) (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hepatic fibrosis using serologic marker</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessment of hepatic fibrosis using AST to Platelet Ratio Index (APRI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Biopsy proven NAFLD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects who are diagnosed with NAFLD with biopsy from September 2016 to October 2018.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Imaging and serologic evaluation of fibrosis and steatosis</intervention_name>
    <description>Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients</description>
    <arm_group_label>Biopsy proven NAFLD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;19 years age

          -  Patients who had elevated aspartate transaminase(AST)/alanine transaminase(ALT) or
             fatty liver on abdominal ultrasonography

          -  Patients who are clinically suspected to have nonalcoholic steatohepatitis(NASH): &gt;40
             years age, BMI &gt;25, multiple features of the metabolic syndrome, presence of diabetes
             mellitus (DM) , fibroscan &gt; 6 kilopascal (kPa), platelet count &lt; 150,000 /ml, and
             other patients suspected to progress clinically or requiring diagnosis

          -  Patients who underwent (&lt;6 months) or will undergo US-guided liver biopsy

        Exclusion Criteria:

          -  Chronic liver disease other than nonalcoholic fatty liver disease(NAFLD) (chronic
             hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis)

          -  Excessive alcohol consumption (weekly men &gt;140g and women &gt;70g)

          -  Fatty liver due to medication

          -  Decompensated liver cirrhosis

          -  Contraindication to magnetic resonance imager(MRI)

          -  Malignancy or other systemic disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Eun Yeon, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prefessor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong Eun Yeon, MD, Ph.D.</last_name>
    <phone>82-2-2626-3010</phone>
    <email>jeyyeon@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Sun Lee, MD</last_name>
    <phone>82-2-2626-3013</phone>
    <email>lys810@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-hoe Song, MBE</last_name>
      <phone>82-2-2626-1635</phone>
      <email>ssessong@korea.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji-young Lee</last_name>
      <phone>82-2-2626-2279</phone>
      <email>ljy@kumc.or.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.</citation>
    <PMID>22488764</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Lenaour G, Vaillant JC, Capron F, Munteanu M, Eyraud D, Ngo Y, M'Kada H, Ratziu V, Hannoun L, Charlotte F. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol. 2012 Jun;10(6):657-63.e7. doi: 10.1016/j.cgh.2012.01.023. Epub 2012 Feb 14.</citation>
    <PMID>22343514</PMID>
  </reference>
  <reference>
    <citation>Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014 Jan;60(1):69-77. doi: 10.1016/j.jhep.2013.09.002. Epub 2013 Sep 12.</citation>
    <PMID>24036007</PMID>
  </reference>
  <reference>
    <citation>Park YS, Lee CH, Kim JH, Kim BH, Kim JH, Kim KA, Park CM. Effect of Gd-EOB-DTPA on hepatic fat quantification using high-speed T2-corrected multi-echo acquisition in (1)H MR spectroscopy. Magn Reson Imaging. 2014 Sep;32(7):886-90. doi: 10.1016/j.mri.2014.04.010. Epub 2014 Apr 24.</citation>
    <PMID>24853467</PMID>
  </reference>
  <reference>
    <citation>Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995 Jun;22(6):696-9. Review.</citation>
    <PMID>7560864</PMID>
  </reference>
  <reference>
    <citation>Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999 Sep;94(9):2467-74.</citation>
    <PMID>10484010</PMID>
  </reference>
  <reference>
    <citation>SCHEUER PJ, WILLIAMS R, MUIR AR. Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol. 1962 Jul;84:53-64.</citation>
    <PMID>14498313</PMID>
  </reference>
  <reference>
    <citation>Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.</citation>
    <PMID>15915461</PMID>
  </reference>
  <reference>
    <citation>Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010 Nov 19;12:69. doi: 10.1186/1532-429X-12-69.</citation>
    <PMID>21092095</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Jong Eun Yeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imager(MRI)</keyword>
  <keyword>Nonalcoholic fatty liver disease(NAFLD)</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

